On May 29, 2014, Nuvo Research (OTCPK:NRIFF) announced that a third party has received FDA approval to market and sell a topical diclofenac sodium 1.5% solution in the U.S. The product is a generic version of Pennsaid® 1.5%. Although this initially sounds like bad news for Nuvo Research, Mallinckrodt (NYSE:MNK), Nuvo's licensee of both Pennsaid® 1.5% and Pennsaid® 2%, has been actively transitioning patients and healthcare providers from Pennsaid®1.5% to Pennsaid® 2% during 2014. While the transition is not yet complete, we have been able to obtain weekly prescription data for the two products, with the data showing that Pennsaid® 2% prescriptions having recently overtaken Pennsaid® 1.5% prescriptions. We forecast this trend to continue, and thus...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|